ProCE Banner Activity

Expert Answers to FAQs: Improving Time to Early Effective Therapy for Resistant Gram-Negative HAP/VAP

Clinical Thought

Expert faculty discuss answers to commonly asked questions about diagnosis, classification of pneumonia, and how local resistance patterns, antibiograms, and other tools can guide timely effective therapy for HAP and VAP.

Released: May 31, 2023

Share

Faculty

Kayla R. Stover Hielscher

Kayla R. Stover Hielscher, PharmD, BCIDP, BCPS, FCCP, FIDSA

Professor of Pharmacy Practice
Program Director, PGY2 Infectious Diseases Residency
University of Mississippi Medical Center
Jackson, Mississippi

Trevor Van Schooneveld

Trevor Van Schooneveld, MD, FSHEA, FACP

Professor, Division of Infectious Diseases
Program Director, Infectious Diseases Fellowship
Medical Director, Antimicrobial Stewardship Program
University of Nebraska Medical Center
Omaha, Nebraska 

Provided by

Provided by ProCE, LLC and Clinical Care Options LLC, in partnership with the Society of Infectious Diseases Pharmacists (SIDP)

ProCE Banner
ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme, LLC

Partners

Society of Infectious Diseases Pharmacists (SIDP)

ProCE Banner

Staff Disclosure

Primary Author

Kayla R. Stover Hielscher, PharmD, BCIDP, BCPS, FCCP, FIDSA

Professor of Pharmacy Practice
Program Director, PGY2 Infectious Diseases Residency
University of Mississippi Medical Center
Jackson, Mississippi

Kayla Stover, PharmD, FISA, FCCP, BCIDP, BCPS: consultant/advisor/speaker: Cidara Therapeutics.

Trevor Van Schooneveld, MD, FSHEA, FACP

Professor, Division of Infectious Diseases
Program Director, Infectious Diseases Fellowship
Medical Director, Antimicrobial Stewardship Program
University of Nebraska Medical Center
Omaha, Nebraska 

Trevor Van Schooneveld, MD: consultant/advisor/speaker: Biomerieux, Thermo Fisher; researcher: AN2 Therapeutics, Insmed.